Literature DB >> 11559525

Identification of cIAP1 as a candidate target gene within an amplicon at 11q22 in esophageal squamous cell carcinomas.

I Imoto1, Z Q Yang, A Pimkhaokham, H Tsuda, Y Shimada, M Imamura, M Ohki, J Inazawa.   

Abstract

Amplification of chromosomal DNA is thought to be one of the mechanisms that activate cancer-related genes in tumors. In a recent study, we identified high copy-number amplification at 11q21-q23 in cell lines derived from esophageal squamous cell carcinomas (ESCs) using comparative genomic hybridization. Because 11q21-q23 amplification has been reported in tumors of various other types as well, gene(s) associated with tumor progression may lie within this chromosomal region. To identify the most likely target(s) for amplification at 11q21-q23, we determined the extent of the amplicon by fluorescence in situ hybridization and then analyzed ESC cell lines for expression levels of 11 known genes and one uncharacterized transcript present within the 1.8-Mb commonly amplified region. Only cIAP1, a member of the IAP (antiapoptotic) gene family, was consistently overexpressed in cell lines that showed amplification. Additionally, the cIAP1 protein was overexpressed in the primary tumors from which those cell lines had been established. The ESC cell lines with cIAP1 amplification were resistant to apoptosis induced by chemotherapeutic reagents. An increase in cIAP1 copy number was also detected in 4 of 42 (9.5%) primary ESC tumors that were not related to the cell lines examined. Because inhibition of apoptosis seems to be an important feature of carcinogenesis, cIAP1 is likely to be a target for 11q21-23 amplification and may be involved in the progression of ESC, as well as other malignancies.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11559525

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  66 in total

1.  A novel target gene, SKP2, within the 5p13 amplicon that is frequently detected in small cell lung cancers.

Authors:  Sana Yokoi; Kohichiroh Yasui; Fumiko Saito-Ohara; Katsumi Koshikawa; Toshihiko Iizasa; Takehiko Fujisawa; Takeo Terasaki; Akira Horii; Takashi Takahashi; Setsuo Hirohashi; Johji Inazawa
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

2.  Increased expression of high mobility group box 1 (HMGB1) is associated with an elevated level of the antiapoptotic c-IAP2 protein in human colon carcinomas.

Authors:  K Völp; M-L Brezniceanu; S Bösser; T Brabletz; T Kirchner; D Göttel; S Joos; M Zörnig
Journal:  Gut       Date:  2005-08-23       Impact factor: 23.059

3.  In Vivo Knockdown of Pathogenic Proteins via Specific and Nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs).

Authors:  Nobumichi Ohoka; Keiichiro Okuhira; Masahiro Ito; Katsunori Nagai; Norihito Shibata; Takayuki Hattori; Osamu Ujikawa; Kenichiro Shimokawa; Osamu Sano; Ryokichi Koyama; Hisashi Fujita; Mika Teratani; Hirokazu Matsumoto; Yasuhiro Imaeda; Hiroshi Nara; Nobuo Cho; Mikihiko Naito
Journal:  J Biol Chem       Date:  2017-02-02       Impact factor: 5.157

4.  Clinical impact of predicting CCND1 amplification using plasma DNA in superficial esophageal squamous cell carcinoma.

Authors:  Shuhei Komatsu; Daisuke Ichikawa; Shoji Hirajima; Hiroki Takeshita; Atsushi Shiozaki; Hitoshi Fujiwara; Tsutomu Kawaguchi; Mahito Miyamae; Hirotaka Konishi; Takeshi Kubota; Kazuma Okamoto; Nobuaki Yagi; Eigo Otsuji
Journal:  Dig Dis Sci       Date:  2014-01-24       Impact factor: 3.199

Review 5.  Reawakening the cellular death program in neoplasia through the therapeutic blockade of IAP function.

Authors:  Casey W Wright; Colin S Duckett
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

6.  Derivatization of inhibitor of apoptosis protein (IAP) ligands yields improved inducers of estrogen receptor α degradation.

Authors:  Nobumichi Ohoka; Yoko Morita; Katsunori Nagai; Kenichiro Shimokawa; Osamu Ujikawa; Ikuo Fujimori; Masahiro Ito; Youji Hayase; Keiichiro Okuhira; Norihito Shibata; Takayuki Hattori; Tomoya Sameshima; Osamu Sano; Ryokichi Koyama; Yasuhiro Imaeda; Hiroshi Nara; Nobuo Cho; Mikihiko Naito
Journal:  J Biol Chem       Date:  2018-03-15       Impact factor: 5.157

7.  Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosis.

Authors:  Luc Friboulet; Catherine Pioche-Durieu; Sandrine Rodriguez; Alexander Valent; Sylvie Souquère; Hugues Ripoche; Abdelmajid Khabir; Sai Wah Tsao; Jacques Bosq; Kwok Wai Lo; Pierre Busson
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

8.  Mathematical modelling of cell-fate decision in response to death receptor engagement.

Authors:  Laurence Calzone; Laurent Tournier; Simon Fourquet; Denis Thieffry; Boris Zhivotovsky; Emmanuel Barillot; Andrei Zinovyev
Journal:  PLoS Comput Biol       Date:  2010-03-05       Impact factor: 4.475

9.  Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer.

Authors:  Fiona M Foster; Thomas W Owens; Jolanta Tanianis-Hughes; Robert B Clarke; Keith Brennan; Nigel J Bundred; Charles H Streuli
Journal:  Breast Cancer Res       Date:  2009-06-29       Impact factor: 6.466

10.  Prediction of CCND1 amplification using plasma DNA as a prognostic marker in oesophageal squamous cell carcinoma.

Authors:  H Takeshita; D Ichikawa; S Komatsu; M Tsujiura; T Kosuga; K Deguchi; H Konishi; R Morimura; A Shiozaki; H Fujiwara; K Okamoto; E Otsuji
Journal:  Br J Cancer       Date:  2010-04-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.